This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

EfficacySafetyDosingSupport & ResourcesSupport & ResourcesVideosMaterials

​​​​The content of this website has been produced in line with the SUTENT® (sunitinib malate) Summary of Product Characteristics for Great Britain. 

Click here for the SUTENT® (sunitinib malate) Prescribing Information for Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page.

Efficacy in mRCCExperience that stands the test of time. ​​​​​​​​​​​​​​Mode Of Action (MOA) 

SUTENT is an inhibitor of multiple receptor tyrosine kinases (TKIs), including the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR), which are expressed in many types of solid tumours and are thought to play a crucial role in angiogenesis.1

Dysregulation of the VEGF pathway is frequently associated with RCC, due to loss of function of the von Hippel-Lindau gene2 making mRCC a highly vascular tumour and underlying why the VEGF pathway continues to be a target in RCC.2

Sutent Video

Watch the mechanism of action video for SUTENT

Real World Data

In 2006:

  • SUTENT was approved for first-line mRCC, transforming the treatment landscape and pushing OS to over 2 years for the first time in the history of the disease3,4,9

Today:

  • SUTENT remains a standard of care in first-line mRCC10
  • Over 300,000 patients have been treated with SUTENT worldwide11
  • Real-world experience has demonstrated OS of over 30 months8

Motzer RJ, et al. Lancet Oncol 2019;20:1370–1385
Gore ME, et al. Br J Cancer 2015;113:12–19
Noize P, et al. Pharmacoepidemiol Drug Saf 2017;26:1561–1569.
Ruiz-Morales J, et al. Eur J Cancer 2016;65:102–108.
Lalani A, et al. Can Urol Assoc J 2017;11:112–117.
Motzer RJ, et al. J Clin Oncol 2009;27:3584–3590.
Motzer RJ, et al. N Engl J Med 2013;369:722–731.

Real-world studies also demonstrate OS benefits with SUTENT®4-8

Motzer RJ, et al. 2009. 
Gore ME, et al. 2015. 
Ruiz-Morales JM, et al. 2016.
Noize P, et al. 2017. 
Lalani AA, et al. 2017.

Data taken from Motzer RJ, et al. 2009. Gore ME, et al. 2015. Ruiz-Morales JM, et al. 2016. Noize P, et al. 2017. Lalani AA, et al. 2017.

EAP, Expanded Access Programme. IMDC, International Metastatic Renal Cell Carcinoma Database Consortium. OS, overall survival. No cross-trial comparisons may be made since trials were conducted using different methodologies and at different time points. Final and investigator review analyses unless otherwise stated.​​​​​​​

*Clinical trial data.Data for MSKCC risk groups. Data for IMDC risk groups 

Safety

See all SUTENT Safety Information 

ViewLoading

AE : Adverse Event 
ESMO:  European Society for Medical Oncology 
IMDC : International Metastatic RCC Database Consortium 
IO : Immuno-Oncology 
mOS : Median Overall Survival 
mPFS : Median Progression-Free Survival 
mRCC : Metastatic Renal Cell Carcinoma 
NHS : National Health Service 
NICE : National Institute for Health and Care Excellence 
OS : Overall Survival 
PFS : Progression-Free Survival 
TKI : Tyrosine Kinase Inhibitor 

References
Chow LQ and Eckhardt SG. J clin Oncol 2007;25:884-896.Rini BI, et al. lancet 2011;378(9807):1931-1939SUTENT® Summary of Product Characteristics for Great Britain click here. SUTENT® Summary of Product Characteristics for Northern Ireland click here.Motzer RJ, et al. J Clin Oncol 2009;27:3584–3590.Gore ME, et al. Br J Cancer 2015;113:12–19.Morales JMR, et al. Eur J Cancer 2016;65:102–108.Noize P, et al. Pharmacoepidemiol Drug Saf 2017;36:1561–1569.Lalani AA, et al. Can Urol Assoc J 2017;11:112–117.Schmidinger M, et al. Ther Adv Urol 2012;4:253–265.Motzer RJ, et al. N Engl J Med 2013;369;722–731.Pfizer. Data on file.
PP-SUT-GBR-0780 September 2023
Safety​​​​​​
IndicationSUTENT (sunitinib malate) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (mRCC) in adults.

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

Sign up now Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​